Supports multidisciplinary research teams developing and validating biomarkers for early pancreatic cancer detection and identifying high-risk patients and precursor lesions likely to progress to cancer.
Funder: National Institutes of Health
Due Dates: February 5, 2027 (New) | March 5, 2027 (Renewal/Resubmission/Revision) | June 5, 2027 (New) | July 5, 2027 (Renewal/Resubmission/Revision) | October 5, 2027 (New) | November 5, 2027 (Renewal/Resubmission/Revision) | February 5, 2028 (New) | March 5, 2028 (Renewal/Resubmission/Revision) | June 5, 2028 (New) | July 5, 2028 (Renewal/Resubmission/Revision) | October 5, 2028 (New) | November 5, 2028 (Renewal/Resubmission/Revision) | February 5, 2029 (New) | March 5, 2029 (Renewal/Resubmission/Revision) | June 5, 2029 (New) | July 5, 2029 (Renewal/Resubmission/Revision) | October 5, 2029 (New) | November 5, 2029 (Renewal/Resubmission/Revision; final closing)
Funding Amounts: Up to $600,000 in direct costs per year for 5 years; no cost sharing required
Summary: Supports multidisciplinary research units developing and clinically validating biomarkers and imaging approaches for early pancreatic cancer detection.
Key Information: All projects must include human subjects and clinical validation, with required consortium collaboration and biospecimen collection.
The National Cancer Institute (NCI) supports Research Units within the Pancreatic Cancer Detection Consortium (PCDC) through U01 cooperative agreements. The program funds early detection of pancreatic ductal adenocarcinoma (PDAC) and characterization of precursor lesions to identify patients at high risk of progression. It targets people with genetic susceptibility, family history, or precursor lesions who could benefit from early intervention.
Research includes bodily-fluid biomarkers, molecular and imaging markers of pancreatic cyst progression, high-risk screening approaches, machine learning, and biomarker validation. The emphasis is on clinically useful tests with high sensitivity and specificity, including integrated molecular and imaging approaches. Research Units also build longitudinal biospecimen resources and share data, specimens, ideas, and expertise across the consortium. Clinical trials are optional.